Dongwoo Hyeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dongwoo Hyeon has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Ho Geol Ryu
Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publicationHong Yeul Lee
Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publication- Hyeonhoon Lee
Healthcare AI Research Institute, Seoul National University Hospital, Seoul, South Korea
1 shared publication - Hyun-Lim Yang
Chungnam National University
1 shared publication - Hyung-Chul Lee
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publication Soomin Chung
Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 18 November 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-13
Reinforcement learning model for optimizing dexmedetomidine dosing to prevent delirium in critically ill patients
Delirium can result in undesirable outcomes including increased length of stays and mortality in patients admitted to the intensive care unit (ICU). Dexmedetomidine has emerged for delirium prevention in these patients; however, optimal dosing is challenging. A reinforcement learning-based Artificial Intelligence model for Delirium prevention (AID) is proposed to optimize dexmedetomidine dosing. The model was developed and internally validated using 2416 patients (2531 ICU admissions) and externally validated on 270 patients (274 ICU admissions). The estimated performance return of the AID policy was higher than that of the clinicians’ policy in both derivation (0.390 95% confidence interval [CI] 0.361 to 0.420 vs. −0.051 95% CI −0.077 to −0.025) and external validation (0.186 95% CI 0.139 to 0.236 vs. −0.436 95% CI −0.474 to −0.402) cohorts. Our finding indicates that AID might support clinicians’ decision-making regarding dexmedetomidine dosing to prevent delirium in ICU patients, but further off-policy evaluation is required.
- 18 November 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-13
Open AccessReinforcement learning model for optimizing dexmedetomidine dosing to prevent delirium in critically ill patients
Delirium can result in undesirable outcomes including increased length of stays and mortality in patients admitted to the intensive care unit (ICU). Dexmedetomidine has emerged for delirium prevention in these patients; however, optimal dosing is challenging. A reinforcement learning-based Artificial Intelligence model for Delirium prevention (AID) is proposed to optimize dexmedetomidine dosing. The model was developed and internally validated using 2416 patients (2531 ICU admissions) and externally validated on 270 patients (274 ICU admissions). The estimated performance return of the AID policy was higher than that of the clinicians’ policy in both derivation (0.390 95% confidence interval [CI] 0.361 to 0.420 vs. −0.051 95% CI −0.077 to −0.025) and external validation (0.186 95% CI 0.139 to 0.236 vs. −0.436 95% CI −0.474 to −0.402) cohorts. Our finding indicates that AID might support clinicians’ decision-making regarding dexmedetomidine dosing to prevent delirium in ICU patients, but further off-policy evaluation is required.